Dendritic cell therapy involves giving a vaccine that stimulates T cells that can be used to fight off glioblastoma, a serious form of brain cancer.
One research article (1) looked at the effectiveness of dendritic cell therapy and the treatment of glioblastoma. It used a phase I trial to see if this type of therapy was safe and possibly effective in human subjects who had glioblastoma.
They studied 12 patients who had glioblastoma and treated them with various amounts of dendritic cells, looking for the safety of this treatment and its effectiveness against the brain cancer. They gave three intradermal vaccinations, given every two weeks. They found that giving this type of treatment was not associated with any toxicity. They followed each patient for five years and found that, regardless of the dose given, the therapy was nontoxic.
Source: 1.Liau MN, et al. Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment. Clin Cancer Res. 2005;11(15).
Dr. Adem Gunes